ApoCell Lands Summit Investment | GenomeWeb

NEW YORK (GenomeWeb News) – Biomarker technology developer ApoCell has received an investment from Boston-based equity investor Summit Partners, which supports life sciences companies.

The amount of the investment was not disclosed.

ApoCell, which spun out from the University of Texas MD Anderson Cancer Center in 2005 and operates out of Houston, will use the funds to continue developing its technology platforms aimed at using biomarker signatures in oncology, diabetes, molecular diagnostics, and drug development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.